Stephen Wang

@shai_wininger @tonyhua64243679 @Tesla @Lemonade_Inc @elonmusk Pls bring it to CA

Our data shows that 50% of @Tesla FSD + @Lemonade_Inc users let it drive autonomously 90-100% of the time. Impressive, @elonmusk!

@DustinHuntwn Nice. One is phase 3.

$IBRX 2 new Anktiva/INKT Cell combo trials listed👇 You can follow me, I'll be tracking $IBRX all the way 🫶

@LamarMK Yes, Tesla should set the price that the take rate can increase significantly

A lot of people don't want to pay $99 a month for FSD. So they don't even try it. Drop the price to $49.99 and suddenly it's an easy decision. Add a 6-month plan for $279 or a yearly plan for $499, and now it's a no-brainer. We saw what happened when Tesla offered the Cybertruck for $59K. Demand took off. Same thing would happen with FSD. Lower the price. Get more people in the door. Let the tech sell itself.

@StateDept Congratulations. Now tell Israel to stop 💣

PRESIDENT TRUMP: The war in Iran has been won. The only one that likes to keep it going is the fake news.

They had quite some completed clinical trials besides bladder cancer related trials, like P2 pancreatic cancer trial, P2 NSCLC trial, and a P2 basket trial across multiple tumor types. The place of clinical trials slowed down during the last few years due to capital constraints. It should start to pick up pace as revenue growth accelerates. The bottom line is Anktiva boosts immune systems which will help all cancer patients (just ask Saudi FDA. They are not dumb), and NK cells play crucial roll in assisting T cell base immunotherapy by killing the cancer cells that managed to hide from T cells. The science is solid.

Maybe you are not used to following companies closely that are working on cancer treatments, but ImmunityBio has very limited clinical results. I follow many other companies, they typically present results at research conferences two to three times per year. They place the posters from these presentations on their website. They submit major data milestones to peer-reviewed journals. They have a file called corporate presentation on their website. It is an extended PowerPoint file that includes the most relevant data to date. ImmunityBio issues many press releases, but they do not include robust information on clinical results. They often prefer to talk about individual patients.

$IBRX FDA Letter Impact What is clear from this letter is that $IBRX is going to need to use much more caution when appearing on TV shows and podcasts. They must avoid claims that are not supported yet with data. Before receiving this public letter, there were other letters sent by the FDA. They state, "OPDP is concerned that, despite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner." Dr, Patrick and the company can face serious legal action if they do not make big changes. My guess is that this is the final warning. The FDA is likely to refer this to the Justice Department if similar statements are made in the future. fda.gov/inspections-co…

@business Anktiva boosts patients’ immune system and hence it helps for all tumor types. FDA is dragging its feet to recognize that, while Saudi FDA is wasting no time to make it available to all cancer patients

ImmunityBio’s shares plunged after the biotechnology company and its billionaire Executive Chairman Patrick Soon-Shiong were hit with a FDA warning letter for false and misleading promotion of its bladder cancer drug Anktiva bloomberg.com/news/articles/…

@AscendingBio I don’t think he needs to mis-present the data. All he has to do is present the details exactly as stated by the clinical results.

This goes beyond a civil lawsuit where the company takes the FDA to court. There is clear evidence in this letter of misrepresentation of data. Many expert witnesses could testify that Dr. Patrick has the knowledge to know better and that this should be seen as an intentional act. If Dr. Patrick continues to misrepresent the data, there can be very serous criminal consequences when the misrepresentation is found to be intentional, involves financial gain, places patients at risk, or violates federal laws. If Dr. Patrick apologizes, corrects the error, and commits to being more careful in the future, it will end there. If he approaches this with defiance, I hold there is a high risk of him facing jail time. If the feds do not pursue this, a state district attorney could. With the company located in California, that is the most likely venue.

“The phase 3 study utilizes Anktiva, a checkpoint inhibitor, and Docetaxel (chemo). That is compared to Docetaxel alone” Just want to point out this design change is likely based on suggestion from FDA. Just doesn’t make sense for the company to make such a change of treatment protocol in a Phase 3 trial.

$IBRX Accelerated Approval for NSCLC? (Part 3 of 3) I often see posts calling for the FDA to immediately grant accelerated approval to Anktiva for Non Small Cell Lung Cancer (NSCLC). The focus for $IBRX has been 2nd line treatment. (They ended a frontline study.) In a phase 2, Dr. Patrick verbally reported that Anktiva plus a checkpoint inhibitor had a median Overall Survival of 14 months. Take a look at slides 22 and 23 in this presentation by Iovance. ir.iovance.com/static-files/5… They found that at 24.5 months after treatment the median duration of response has not been met. That means more than half are still alive at 24.5 months and maintaining the response to treatment. So, the Iovance results are likely to be years more of survival than ImmunityBio. Yes, TIL therapy is more challenging, but it is worth it with results like this. They do not have approval yet from the FDA for this type of cancer. They do not protest or go overseas. They work to fully enroll the study before going to the FDA. With more data like this, the Accelerated Approval path should be open to them. They are also advancing new versions that are even more effective. A recent study compared Dato-DXd to Docetaxel in the same context (previously treated NSCLC without actionable genomic alterations). They found Median PFS: 4.4 vs 3.7 months (HR 0.75, P=0.004). Median OS: 12.9 vs 11.8 months (HR 0.94, P=0.530 – not statistically significant). They dropped the drug from this indication after getting an OS of 12.9 months. ImmunityBio took their 14 month OS results to Saudi Arabia and sought approval. On the last call, Dr. Patrick proclaimed this result was amazing and they had doubled median OS from 7 months to 14. If you do not study competitors, this sounds good. There are several reasons the FDA will not accept Anktiva under accelerated approval for NSCLC at the current stage. One is that the phase 2 study used Anktiva and a checkpoint inhibitor. The phase 3 study utilizes Anktiva, a checkpoint inhibitor, and Docetaxel (chemo). That is compared to Docetaxel alone. This resets everything when you make that kind of a change. If you thought the phase 2 combo was good, why did you change it in the phase 3? Accelerated approval by FDA rules include using one variable that you establish as a predictor for a variable you will not know until the future. That does not apply here. ImmunityBio already has Overall Survival data for the phase 2. It might be possible to submit the new triple combo data to the FDA a year or so after full enrollment using the phase 3 interim results under Accelerated Approval. Maybe, you have progression free survival data by the 10-month mark. It would take dramatically different progression free survival numbers for treatment versus control. It would need to appear that Overall Survival numbers for the treatment group would not be available for a year or more. If it looks like the treatment group is likely to have median survival of about 14 months and 7 months for the control, why not wait another 6 months and submit the Overall Survival numbers? That OS data is going to be available during the FDA review process. The FDA will likely pause and delay the approval process in order to consider the new data. Another factor for the phase 3 study is that it is using a 3 drug combo where the design does not lend itself to determining the contribution made by Anktiva. It is possible that the FDA requires another study to determine this contribution. They may say, "It could be that adding the checkpoint inhibitor to Docetaxel is what prompted treatment versus control differences." I am not ruling out that Anktiva is eventually approved for 2nd line NSCLC by the FDA. My point is that there is not a short-term path. I encourage you to go check my work. Go read the regulations on the FDA website. Look up other companies that were recently granted Accelerated Approval. Keep in mind that most companies do not submit under the AA program unless they have informal support from FDA staff. If a company is told they likely need more data to support a surrogate endpoint, they will typically not submit until they have that data in hand. The basic Accelerated Approval structure is based on law passed by Congress. If you want this to be different you need to get new laws passed by Congress.

@wintonARK @elonmusk Cheaper insurance for using FSD will change that.

It really is bizarre. Most of my friends don't have FSD (or a Tesla). And it is the single biggest lifestyle difference between us. They drive their cars. My car drives me. They don't get how much--even at its current capability-level--the product changes life-feel. FSD truly is a mass luxury product. That it is still so narrowly enjoyed is mind-bending.

@JoeTegtmeyer MYL?

Well this is interesting at Giga Texas today … what do YOU think this is? 🤔😎

@TylerHardt Maybe EUV machines from China? It will way cheaper when it comes out

I notice you failed to mention how $TSLA is going to do any of this without buying an EUV Lithography Machine from $ASML considering they are sold out through 2028? Seems like an important detail. $TSLAQ

@BarackObama Why health insurance skyrocketed? I am paying $1400 per month, not including company’s contributions

The day the Affordable Care Act passed was one of my proudest moments as president, because it meant that millions of Americans would have access to health care, some for the first time. The ACA also prevented insurance companies from denying people with pre-existing conditions coverage, allowed young people under the age of 26 to remain on their parents’ plan, expanded Medicaid, and so much more. But the ACA was always meant to be a first step. We still have to do more to expand access and make health care more affordable for everyone.

@BoBbyPleWniaK Millions of dollars salary

Shocked Elon didn’t announce a new Elon company to build all this out. Because why would new engineers want to work on this project if it involves Tesla and no ability to get filthy rich since the stock can’t provide the returns like a new Elon startup company.

@GerberKawasaki Say Tesla, not the cheap EVs

It’s simple, buy an EV. Get solar, if possible, with a battery system. Get heat pumps for your heat and air. And no need for oil and gas at all. Even just heat pumps and an EV will cut your cost of living by a ton. Lots of cheap EVs out there right now.

@netanyahu Stop the war

Iran has proven again in the last 48 hours that it is the enemy of civilization and a danger to the free world: targeting children, families, and the elderly with terror missiles, threatening Jerusalem’s holy sites, launching long-range missiles, and trying to blackmail the world through the Strait of Hormuz. I ask the leaders of the free world: what are you waiting for? Israel is fighting not only for itself, but for all of you

@OlenaRohoza Election is controlled by money

🇺🇸🧐Tell me, how could it happen that in the richest and most advanced country, a group of complete idiots managed to come to power?

@RepDonBeyer Lesson No 1 for voters: don’t vote for old people

It's important not to shy away from candidly discussing the President's increasingly erratic behavior. His worsening instability is a clear and growing threat, not only to the American people but to the world.

@MarioNawfal The start of human self destruction

🚨🇮🇷 BREAKING: Iran just made the one threat that could bring the Gulf to its knees Iran's military headquarters warned that if its energy infrastructure is attacked, all energy, IT, and desalination facilities belonging to the U.S. and its allies in the region will be targeted. Desalination. That's the word that matters most here. Gulf nations get most of their drinking water from desalination plants. One report estimated that hitting Saudi Arabia's Jubail plant alone would force the evacuation of Riyadh's 8.5 million residents within a week. Trump just gave Iran 48 hours to open Hormuz or he starts destroying power plants. Iran just responded by putting a target on the one thing Gulf nations can't survive without: clean water. Source: @sentdefender

@bradsferguson What’s the extra benefit of prolonging the war?

I’m seeing many people jump to conclusions about this stmt from Trump. They are saying the 🇺🇸 is done with the military campaign in Iran. Maybe it’s my algo, but an overwhelming majority says so. imo, it’s premature.